We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Modern Water Plc | LSE:MWG | London | Ordinary Share | GB00B1XF5X66 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.45 | 2.40 | 2.50 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
18/8/2020 07:47 | now lagging SKIN, could be a trade. Well done those in SKIN, salute you. | onehanded | |
18/8/2020 07:47 | Where did end of August date come from. Im sure they have till end of Sept to publish? | riskblue | |
18/8/2020 07:44 | awesome, not long to wait then eh | monkey puzzle | |
18/8/2020 07:44 | yes and the boss did stay nothing to worry about a while back. I am really thinking it could be set up for something special and rather fully loaded and ready. We will see.... | onehanded | |
18/8/2020 07:42 | hamida there are now just 8 working days to the end of this month. | 2magpies | |
17/8/2020 20:39 | Video on the latest award winning #MicrotoxLX laboratory testing platform from #MWG #ModernWater Still a gold standard for toxicity testing after 30 years around the world. https://twitter.com/ | hamidahamida | |
17/8/2020 16:59 | There is no need for SKIN to acquire MWG. They are partners and have complimentary techs so will work effectively and well together. No need to merge at all. The set up seems good with 60/40 split in favour of MWG with the reagent profitability and with the AI SKIN would likely have the larger portion. I am looking forward to the long awaited AR RNS and wonder if they'll give us a H1 update given we'll be nearly 2 months past it. We know what FY19 looks like but it's about H1 and of course H2 with hopefully nearly 3,000 Microtox units being upgraded with AI. I hope we get a H1 trading update as well as some decent outlook commentary. | tickboo | |
17/8/2020 11:29 | Proud owner of 1m of these now. But anyone saying they're worth £1 can have all mine for 50p today... limited offer, of course. | brucie5 | |
17/8/2020 10:51 | I've raised this before on a couple of occasions and it tended to be dismissed by most. To be fair though things have moved on a tad and are doing so at cracking pace. | flashheart | |
17/8/2020 10:44 | Skin would be the bigger player so would need to make an offer for MWG and would be in SKIN shares, of course all of this is pure speculation fwiw. | monkey puzzle | |
17/8/2020 10:38 | Well GB is CEO of one and Chairman of the other so a merger not out of the question. | eeza | |
17/8/2020 10:36 | Now there's a thought | monkey puzzle | |
17/8/2020 10:29 | There is a case for both to be bought out and merge into one new company, that would be one great company lol. | onehanded | |
17/8/2020 10:26 | Agree re mkt value and shares in issue favours MWG, that said SKIN's revenue streams are greater. FWIW, my rational if you already hold MWG shares (and funds allow) you almost have to hold SKIN, due to (for the short term) they appear reliant on SKIN and their Covid trials to boost their resurgence. The same is not the case for SKIN All in my opinion of course and good luck in whatever you choose. | paulcon1 | |
17/8/2020 09:49 | I always have favoured MWG as it has some big contracts already and should be adding. The deal with SKIN in 60% in their favour and with less shares / warrants around it could go up very quickly. It could get to 10p by the end of the year easily. BUT all depends on contracts and the covid real time detection. | onehanded | |
17/8/2020 09:19 | Exactly. Just hold both is the simple answer. | mam fach | |
17/8/2020 08:56 | and of course MWG could gain a lot more quickly with an mcap of £11mm v £30m for skin but who knows as skin have more products etc. | monkey puzzle | |
17/8/2020 08:52 | I'm holding both too. Got more of MWG simply because there are less shares in Issue. | mam fach | |
17/8/2020 08:27 | Judi, I avoided that by splitting 50/50 between them | monkey puzzle | |
17/8/2020 08:27 | Not quite but close | monkey puzzle | |
17/8/2020 08:25 | Thanks for the quick reply Monkey Puzzle, but from that article, does it seem that they are already ready to go?? John | 2350220 | |
17/8/2020 08:25 | Guys which to buy MWG or SKIN? | judijudi | |
17/8/2020 08:22 | To me it shows that the potential is huge, competition is good (look as the way Samsung and Apple have grown massively with both in the smartphone market). Having more players just drives up demand. It's a good thing. No one likes only having a single monopoly supplier. | monkey puzzle | |
17/8/2020 08:05 | A pilot program has been launched for a rapid COVID-19 detection test, employing a revolutionary device that uses light waves to analyze molecular content. Israeli startup Newsight is collaborating with Sheba Medical Center to identify and classify evidence of coronavirus in the body in less than a second, using a sample of fluid – blood serum or saliva. Concrete results of the trial are expected within the coming months. Newsight employs spectral technology (using light waves) to develop advanced image sensor chips for 3D machine vision and spectral analysis. The sensors have been integrated in dozens of devices and solutions in various fields including robotics and automotive industrial manufacturing. The use of spectral technology to detect the presence of pathogens is not new, but to date, has necessitated a cumbersome, costly device. The new innovation being piloted with Sheba involves a cost-effective chip. Imagine us having waste monitoring and now something for personal testing in real time too....world is big enough to accommodate more than one supplier, could be huge | monkey puzzle |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions